

1 **Analytical validation of a multi-protein, serum-based assay for disease activity**
2 **assessments in multiple sclerosis**

3

4 Ferhan Qureshi,^{1*} Wayne Hu,^{1*} Louisa Loh,¹ Hemali Patel,¹ Maria DeGuzman,¹
5 Michael Becich,^{1†} Fatima Rubio da Costa,^{1†} Victor Gehman,^{1†} Fujun Zhang,^{1†}
6 John Foley,² Tanuja Chitnis³

7 ¹Octave Bioscience, Inc., Menlo Park, CA, USA

8 ²Rocky Mountain Multiple Sclerosis Clinic, Salt Lake City, UT, USA

9 ³Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

10 *These authors contributed equally to this work

11 †Employee of Octave Bioscience, Inc., at the time the study was completed

12

13 **Correspondence**

14 Ferhan Qureshi

15 1440 Obrien Drive, Suite B

16 Menlo Park, CA 94025, USA

17 Email: fqureshi@octavebio.com

18 Phone: 650-224-3072

19 Fax: 650-479-8876

20

21 **Abbreviations:**

22 %CV, percent coefficient of variation; APLP1, amyloid beta precursor-like protein 1;

23 CCL20, C-C motif chemokine ligand 20; CD6, cluster of differentiation 6; CDCP1,

24 CUB domain-containing protein 1; C_{max}, maximum concentration; CNS, central

25 nervous system, CNTN2, contactin 2; COL4A1, collagen type IV alpha-1; conc,

26 concentration; CSF, cerebrospinal fluid; CXCL9, chemokine (C-X-C motif) ligand 9

27 (MIG); CXCL13, chemokine (C-X-C motif) ligand 13; DMT, disease-modifying

28 therapy; DNA, deoxyribonucleic acid; FLRT2, fibronectin leucine-rich repeat

29 transmembrane protein; Gd⁺, gadolinium positive; GFAP, glial fibrillary acidic protein;

30 GH, growth hormone; HAMA, human anti-mouse antibodies; HCl, hydrochloride; IL-

31 12 β , interleukin-12 subunit beta; LLOQ, lower limit of quantitation; LOQ, limit of

32 quantitation; mAb, monoclonal antibody; Max, maximum; Min, minimum; MOG,

33 myelin oligodendrocyte glycoprotein; MRI, magnetic resonance imaging; MS, multiple
34 sclerosis; MSDA, Multiple Sclerosis Disease Activity; Na, sodium; NfL, neurofilament
35 light chain; OPG, osteoprotegerin; OPN, osteopontin; PCR, polymerase chain
36 reaction; PEA, Proximity Extension Assay; PRTG, protogenin; qPCR, quantitative
37 polymerase chain reaction; R^2 , coefficient of determination; RA, rheumatoid arthritis;
38 RF, rheumatoid factor; SD, standard deviation; SERPINA9, serpin family A member
39 9; TNFRSF10A, tumor necrosis factor receptor superfamily member 10A (TRAIL-R1);
40 TNFSF13B, tumor necrosis factor superfamily member 13B (BAFF); ULOQ, upper
41 limit of quantitation; VCAN, versican core protein

42

43 **Key words:**

44 Analytical characterization, analytical validation, biomarker, multiple sclerosis,
45 proximity extension assay

46

47 **Total word count:** 3964 (5000 maximum)

48 **Running head:** Analytical Validation of a Serum-Based Assay for Disease
49 Activity Assessments in Multiple Sclerosis

50 **Previous presentation:** Part of this work, namely analytical validation of the
51 individual biomarkers in the MSDA Test, was previously
52 presented at the ACTRIMS 2021 Forum, Virtual (February
53 25–27, 2021) and analytical validation of the Disease
54 Activity Score and 4 Disease Pathway Scores, was
55 previously presented at the ACTRIMS 2022 Forum, West
56 Palm Beach, Florida (February 24–26, 2022)

57 **Clinical relevance**

58 Multiple sclerosis (MS) is a chronic, neurodegenerative, immune-mediated disease of
59 the CNS. MS has a complex disease course with variable clinical outcomes. Although
60 many treatments are effective in early stages of the relapsing/remitting form of the
61 disease, early diagnosis and treatment are critical to managing disease activity and
62 slowing disease progression. One of the major areas of focus in MS research is the
63 identification of biomarkers in biological fluids, such as cerebrospinal fluid or blood, to
64 track pathogenesis, disease activity, and disease progression, which can lead to
65 individualized disease management and improved quality of care. Currently, there
66 are no validated clinical tests that leverage multiple blood biomarkers to track disease
67 activity or progression in patients with MS. Herein, we describe the analytical
68 characterization and validation of a multi-protein, serum-based assay panel
69 developed using Olink[®] PEA methodology. We demonstrate the extensive
70 characterization of this multi-protein, serum-based assay and establish its accuracy,
71 precision, sensitivity, and robustness. This report will be followed by a
72 complementary clinical validation study investigating the correlation between the
73 proteomic assay results and relevant clinical and radiographic endpoints for patients
74 with MS.

75 **Abstract**

76 **Purpose:** To characterize and analytically validate the MSDA Test, a multi-protein,
77 serum-based biomarker assay developed using Olink[®] PEA methodology.

78 **Experimental design:** Two lots of the MSDA Test panel were manufactured and
79 subjected to a comprehensive analytical characterization and validation protocol to
80 detect biomarkers present in the serum of patients with MS. Biomarker
81 concentrations were incorporated into a final algorithm used for calculating four
82 Disease Pathway scores (Immunomodulation, Neuroinflammation, Myelin Biology,
83 and Neuroaxonal Integrity) and an overall Disease Activity score.

84 **Results:** Analytical characterization demonstrated that the multi-protein panel
85 satisfied the criteria necessary for a fit-for-purpose validation considering the assay's
86 intended clinical use. This panel met acceptability criteria for 18 biomarkers included
87 in the final algorithm out of 21 biomarkers evaluated. VCAN was omitted based on
88 factors outside of analytical validation; COL4A1 and GH were excluded based on
89 imprecision and diurnal variability, respectively. Performance of the four Disease
90 Pathway and overall Disease Activity scores met the established acceptability
91 criteria.

92 **Conclusions and clinical relevance:** Analytical validation of this multi-protein,
93 serum-based assay is the first step in establishing its potential utility as a quantitative,
94 minimally invasive, and scalable biomarker panel to enhance the standard of care for
95 patients with MS.

96 **What is known and what is new in your work?**

97 **What's known**

98 ☐ Multiple sclerosis (MS) has a complex disease course with variable clinical
99 outcomes; early diagnosis and treatment are critical to management of MS.

100 ☐ One key focus in MS research is the identification of biomarkers in biological
101 fluids, such as cerebrospinal fluid or blood, to track pathogenesis, disease activity,
102 and disease progression, which may lead to individualized disease management
103 and improved quality of care.

104 ☐ There currently are no validated clinical tests that leverage multiple blood
105 biomarkers to track disease activity or progression in patients with MS.

106 **What's new**

107 ☐ The MS Disease Activity (MSDA) Test is a multi-protein, serum-based biomarker
108 assay designed to quantitatively measure disease activity using the protein levels
109 of biomarkers present in the serum of patients with MS.

110 ☐ In this study, we evaluated 21 biomarkers, 18 of which were selected for inclusion
111 in the MSDA Test, and extensively characterized the MSDA Test (individual
112 biomarkers and algorithmic scores) by establishing the accuracy, precision,
113 sensitivity, and robustness of the assay.

114 ☐ This study serves as a critical first step in the validation of this multi-protein,
115 serum-based assay, which will be a quantitative, minimally invasive, and scalable
116 tool to improve MS disease management.

117 **1 INTRODUCTION**

118 Multiple sclerosis (MS) is a chronic, neurodegenerative, immune-mediated disease of
119 the CNS, characterized by inflammatory demyelination and neuronal damage.[1,2]

120 MS has a complex disease course with variable symptoms or manifestations that can
121 range from mild and self-limiting to severe.[1] The clinical course, after the first
122 clinical manifestation of the disease, or clinically isolated syndrome, can vary.[3] The
123 damage caused by MS typically leads to relapses, or acute attack of symptoms,
124 followed by progressive disease.[4] Most treatments are effective in early stages of
125 the relapsing/remitting form of the disease;[4,5] however, a delay in treatment can
126 lead to irreversible damage.[6] Studies show that the extent of remyelination in early
127 MS is greater than in chronic MS.[7] Clinical studies are underway to explore
128 treatments targeting remyelination, which may slow or offset disease progression.[8]

129 The McDonald Criteria, designed to improve the accuracy of MS diagnosis,
130 established the use of MRI to show the accrual of lesions over time and space.[9]
131 The revised McDonald Criteria substituted CSF oligoclonal immunoglobulin G bands
132 for the second clinical/MRI finding.[10] Nonetheless, use of any of these
133 assessments do not always accurately predict disease activity, course, progression,
134 recurrence, or response to treatment.[11-13] As such, there is an unmet clinical need
135 for objective and quantitative measures that can accurately diagnose MS, monitor
136 disease activity, and promote individualized disease management.[13,14]

137 One major area of focus in MS is the identification of biomarkers in biological
138 fluids, such as CSF or blood, to track pathogenesis, disease activity, and
139 progression.[14,15] One of the key therapeutic strategies in MS is to reduce relapse,
140 lesions, and brain atrophy at all disease stages.[4] As a result, new biomarkers for
141 early MS diagnosis and disease activity monitoring can lead to prevention of disease

142 progression, potentially reducing the patient's level of disease worsening.[14] The
143 dynamic range of proteins in CSF presents challenges when differentiating small
144 disease-specific changes from inherent inter-individual differences, especially as it
145 relates to methodological variations.[16,17] CSF collection also requires invasive
146 procedures, such as lumbar puncture. On the other hand, blood-based collection of
147 biomarkers allows for safe, quick, and easy collection.[14] With these considerations,
148 detection of biomarkers in blood is a viable and attractive option for the accurate
149 diagnosis and assessment of disease activity and progression in MS. However, there
150 currently are no validated clinical tests that leverage multiple blood biomarkers to
151 track disease activity or progression in patients with MS.[18]

152 Development of multi-protein assays can be challenging. Each protein
153 biomarker requires specific conditions and methodologies for optimal quantification.
154 The optimal multi-protein assay should be designed so that stability and integrity of
155 all biomarker proteins are maintained and optimized to eliminate cross-reactivity.[19]
156 Larger scale, proteomic techniques allow higher throughput of samples and more
157 timely readout. However, maintaining robustness, repeatability, and sensitivity is
158 challenging, yet critical, to the validation of a multi-protein biomarker panel.[20]

159 Analysis of multiple proteins may more accurately represent the various
160 pathways, processes, and cell types involved in complex disease states and has the
161 potential to deliver more personalized medicine for MS.[20-23] Single proteins may
162 not perform well alone as diagnostic or prognostic markers. However, as part of a
163 multi-protein assay, they may contribute to a clinically useful model when combined
164 with other proteins and biomarkers.[21] Therefore, multi-protein assay platforms have
165 been characterized and validated for complex disease states.[19,21,22,24]

166 The MSDA Test is a multi-protein, serum-based biomarker assay designed to
167 quantitatively measure disease activity using the protein levels of biomarkers present

168 in the serum of patients with MS. Our custom multi-protein assay panel was
169 developed using the Olink[®] PEA (Olink Proteomics, Uppsala, Sweden) methodology
170 described previously (**Figure S1**).[19] Herein, we describe the comprehensive
171 analytical characterization and validation of the MSDA Test to satisfy the criteria
172 necessary for a fit-for-purpose validation considering the assay's intended clinical
173 use.

174

175 **2 EXPERIMENTAL SECTION**

176 **2.1 Assay development**

177 Twenty-one biomarkers were selected for inclusion in the custom assay panel based
178 on statistical associations with clinical and radiographic endpoints as demonstrated in
179 feasibility studies for which >1400 proteins were screened using 2 immunoassay
180 platforms (**Table S1**). These feasibility studies investigated biomarker associations
181 (single-protein and multi-protein) in both cross-sectional and longitudinal samples
182 relative to several radiographic and clinical MS endpoints, including clinically defined
183 relapse versus remission (exacerbation versus quiescence), the presence and count
184 of gadolinium-enhanced lesions on a matched MRI, annualized relapse rate, and
185 Expanded Disability Status Scale. From these studies, the custom panel of 21
186 proteins was selected with a primary focus on the detection and prediction of disease
187 activity status. The 21 proteins were chosen based on their statistical significance
188 relative to the aforementioned endpoints and with the intent to comprehensively
189 survey the biological pathways, mechanisms, and cell types associated with MS
190 pathophysiology as determined via literature review, protein-protein interaction
191 modeling, gene set enrichment, and spatial expression profiling.[25] Dynamic range
192 of the individual protein assays was considered, as well as the intent to develop a

193 single multi-protein immunoassay panel for which each protein could be measured in
194 an undiluted serum sample. The MSDA Test algorithm consisting of 18 biomarkers
195 included in the panel was finalized in a subsequent clinical validation study for which
196 independent sample sets were analyzed. The final model was trained and validated
197 relative to the presence and count of gadolinium-enhanced lesions.

198 Serum pools ($n=4$) were included on all runs during assay discovery and
199 development. They were procured in large volumes, aliquoted, stored at -65°C , and
200 run in triplicate. Serum pools were used solely to assess the analytical performance
201 of the assays and served as process controls to determine acceptability of future
202 analytical runs. The SD of repeated measurements was applied to the expected
203 concentrations. Two assay kit lots of the panel were manufactured for which critical
204 reagents were varied to the extent possible.

205 **2.2 Description of the two-layer stacked classifier algorithm for determination** 206 **of the overall Disease Activity score**

207 A two-layer, L2-penalized logistic regression stacked classifier model was developed
208 and clinically validated in a separate study that optimized the model's performance to
209 classify serum samples based on the presence of gadolinium-enhancing lesions (0
210 lesions or ≥ 1 lesions) on an MRI administered within 60 days of blood draw.[26] In
211 the first layer of the model, individual protein concentrations in \log_{10} which were
212 demographically corrected for age and sex and LOQ-imputed (referred to as adjusted
213 concentrations) were used as inputs into the four Disease Pathway models
214 (Immunomodulation, Neuroinflammation, Myelin Biology, and Neuroaxonal Integrity).
215 The second layer of the model used the adjusted protein concentrations and the

216 output (eg, the probability) of the Disease Pathway models as meta features to
217 calculate an overall Disease Activity score (**File S1, Supporting Information**).
218 Thresholds were established, which corresponded to low (1.0–4.0), moderate
219 (4.5–7.0), and high (7.5–10.0) Disease Activity scores. Analytical characterization
220 and validation of the individual biomarkers were factors used to determine inclusion
221 of those biomarkers in the algorithm.

222 **2.3 Incurred sample reanalysis**

223 Incurred sample reanalysis was performed to characterize precision and robustness
224 for the individual biomarkers and the Disease Activity and Disease Pathway scores.
225 Forty-eight individual samples from patients with MS were repeatedly analyzed
226 across 10 plates over ≥ 5 days with varied equipment, reagents, location, and
227 personnel. Acceptability criteria for individual biomarkers was an average %CV
228 $\leq 20\%$, and average SD at all established Disease Activity score levels of ≤ 1.0 units.
229 The 48 samples broadly represented the expected range of biomarker values and
230 Disease Activity scores in the real-world MS population.

231 **2.4 Assay accuracy, precision, and sensitivity**

232 Accuracy for each analyte was determined by mixing serum samples at different
233 ratios and evaluating the percent recovery of the observed concentration relative to
234 the expected concentration. Sample mixing enabled the accuracy assessment to be
235 performed using endogenous protein versus a recombinant protein source. Expected
236 concentrations were calculated by applying the targeted ratios of unmixed samples.

237 The ratios of sample mixtures with two samples were 25%:75%, 50%:50%, and
238 75%:25%. The ratios of sample blends for mixtures with four samples were
239 25%:25%:25%:25% and 40%:10%:40%:10%. Additionally, accuracy was also
240 evaluated for the Disease Pathway and Disease Activity algorithms by correlating
241 observed scores with expected scores using the same sample mixtures created for
242 the individual analyte assessments.

243 Intra- and inter-assay precision was measured for each analyte. The %CV was
244 determined using serum pools enabling the assessment to be performed using
245 endogenous protein. Serum pools were manufactured to represent patients with
246 shorter and longer MS disease duration, those with inflammatory disease
247 (rheumatoid arthritis), and one healthy control. Acceptability criteria for intra- and
248 inter-assay precision was established as %CV $\leq 15\%$ and $\leq 20\%$, respectively.

249 Sensitivity was defined as the assay's ability to accurately and precisely detect
250 low concentrations of a given substance in biological specimens. To establish the
251 ULOQ and LLOQ, a LOQ panel was manufactured during assay development. For
252 each analyte, four levels were targeted near the anticipated upper limit (ULOQ 1–4)
253 and four levels were targeted near the anticipated lower limit (LLOQ 5–8). The
254 targeted concentrations were based on expected real-world MS patient sample
255 distributions, the shape of the standard curve, and location of asymptotes. The LOQ

256 panel was run in triplicate over two lots (≥ 5 runs per lot) and fit to the standard curve.
257 Accuracy, defined as 80–120% recovery relative to the expected concentration and
258 precision (inter-assay %CV $\leq 20\%$), were used to establish the acceptability criteria
259 and determine the LLOQ and ULOQ of each analyte. Additionally, individual LOQs
260 were assessed and established separately for each kit lot. The most conservative
261 LOQ levels with acceptable accuracy and precision parameters for both lots were
262 used to establish the final LLOQ and ULOQ.

263 Undiluted serum samples were run in the MSDA Test and as a result, no
264 dilution factor was accounted for in the sensitivity analysis. Therefore, the LLOQ and
265 ULOQ define both the analytical measurement range and the reportable range of the
266 assay. Serum samples that recovered either above the ULOQ or below the LLOQ
267 were reported at the established LOQ concentration (referred to as LOQ imputation).
268 MS serum samples were used to establish MS reference ranges for each biomarker.
269 A diverse set of patient samples were used throughout the assay development
270 process and for the analytical validation studies. A total of 1645 samples from nine
271 deeply phenotyped cohorts were analyzed primarily for evaluating associations of
272 biomarkers with MS disease activity and disease progression endpoints. Additional
273 samples from both patients with MS and other disease states were procured for
274 specific analytical characterization experiments. The 1645 samples that were
275 analyzed for the associations of biomarkers with MS endpoints were combined in the
276 subsequent analysis to establish MS reference ranges. These samples were
277 collected both retrospectively and prospectively from nine US and international sites

278 and broadly represent the real-world MS population. The mean \pm SD age of these
279 patients at the time of the blood draw was 40.85 ± 11.0 years, with a mean \pm SD
280 disease duration of 8.39 ± 8.0 years; 72.8% of the patients were female. For race, the
281 top 3 categories were White (81.4%), unknown/not reported (13.5%), and
282 Black/African American (2.7%). The primary endpoint used to train the finalized
283 MSDA Test algorithm was the presence and count of gadolinium-enhancing lesions
284 on an MRI administered within close proximity to the blood draw. For the 1645 patient
285 samples, 1326 had available gadolinium-positive (Gd+) lesion counts and 53.0% of
286 the patient samples had ≥ 1 Gd+ lesion. The linear interpolation method was used to
287 establish the 95% interval (2.5th and 97.5th percentiles).[27] The percentile relative
288 to these reference ranges are presented with their protein concentrations.

289 **2.5 Assay interference**

290 Assay interference was defined as the effect of a substance present in the sample
291 altering the correct value of the result or the recovery of samples in the assay. Since
292 patients with MS may be treated with a variety of drugs, potential interference of
293 drugs was tested to determine if their presence would affect measurement of the
294 individual protein biomarkers. Concentrations of common prescriptions, over-the-
295 counter drugs, common MS drugs, and DMTs were spiked into serum samples
296 (**Table S2**). Concentrations of common prescription and over-the-counter drugs were
297 determined by Sun Diagnostics (New Gloucester, ME, USA) using a commercially
298 available test kit. DMTs were targeted at two times C_{max} from pharmacokinetic
299 studies, or the highest possible concentration allowable for spiking with the procured
300 interferent stock. Finally, a universal mAb standard was tested at two concentrations
301 (424 and 7.93 $\mu\text{g/mL}$) to cover the two times C_{max} of several mAb DMTs.
302 Endogenous substances (hemoglobin, bilirubin, and lipids) and heterophilic
303 antibodies (RF and HAMA) were also measured. For most interferent substances, the

304 acceptability threshold, or median recovery, for the interference assessment was
305 established as 80–120% relative to a corresponding spike control, except for HAMA
306 for which percent recovery of sample mixtures was evaluated (**File S2, Supporting**
307 **Information**).

308 **2.6 Diurnal variability**

309 Patient serum samples were collected at days 1–5 and day 12 to characterize
310 biomarker level fluctuations. For each of the six time points per patient, the %CV and
311 the percentage difference of the observed protein concentration relative to the
312 average concentration at all time points were calculated.

313 **2.7 Sample stability**

314 In an initial experiment, stability studies for four serum samples were performed to
315 determine the effect that storage and processing conditions can have in a clinical
316 setting. Stability was assessed at the following four temperatures: –65°C or below
317 (–80°C), –10°C or below (–20°C), 2–8°C (4°C), and room temperature (18–25°C) at
318 the following time points: 4 hours (for 4°C and room temperature) and days 1, 3, 7,
319 14, and 28 (for –20°C, 4°C, and room temperature). The results from –20°C, 4°C,
320 and room temperature were compared with the control storage condition (–80°C). In
321 a follow-up study, the stability of storage of 14 samples was evaluated at 4°C at days
322 1–3 and 7 compared with a control storage condition (–80°C) to establish the
323 duration of time samples that can be stored at 4°C. Five freeze-thaw cycles,

324 performed at -65°C or below, were also evaluated using four MS serum samples
325 compared with fresh samples.

326

327 **3 RESULTS AND DISCUSSION**

328 **3.1 Analytical characterization and validation**

329 Experiments were performed between July 2020 and July 2021. Fifty-one plates were
330 run (40 and 11 plates using the first and second lots of manufactured kits,
331 respectively).

332 Based on the analytical validation and characterization of individual
333 biomarkers described below, the 18 out of 21 biomarkers that were included in the
334 algorithm were determined to have acceptable analytical performance. GH and
335 COL4A1 were excluded from the algorithm based on the analytical characterization
336 studies described below. VCAN was not incorporated into the final algorithm due to
337 biostatistical factors unrelated to analytical performance.

338 **3.2 Incurred sample reanalysis**

339 All individual biomarkers were determined to have a mean %CV <20% and met
340 established acceptability criteria (**Figure 1A**). The Disease Activity score and the four
341 Disease Pathway scores demonstrated reproducible results throughout the range of
342 scores (**Figures 1B–1F**). For the Disease Activity score, the average SD across 48
343 samples was observed to be 0.3 score units, which is less than one interval (0.5) on
344 the reportable scale, and as a result, met acceptability criteria. Additionally, incurred
345 sample reanalysis showed robustness and equivalency of the assay between lots
346 and laboratories, with the exception of COL4A1 (**Table S3**).

347 **3.3 Assay accuracy, precision, and sensitivity**

348 Samples for the accuracy assessment were selected from an internal MS cohort
349 ($n=64$) to target both high and low concentrations for the individual biomarkers
350 relative to the MS population. Twenty mixed samples from four selected samples
351 were analyzed for each biomarker. Minimum percent recovery for each biomarker
352 ranged from 78% to 89%; the maximum percent recovery for each biomarker ranged
353 from 99% to 124%. The median percent recovery ranged from 91% to 100% (**Figure**
354 **2A**). Additionally, the Disease Pathway and overall Disease Activity scores were
355 calculated for both observed and expected concentrations of the various sample
356 mixtures. The observed calculated scores correlated with the expected scores; R^2
357 ≥ 0.85 was established as the acceptability criteria (**Figures 2B–2F**).

358 Twelve replicates per serum pool were analyzed on a single plate for the intra-
359 assay precision assessment; ≤ 51 values per serum pool were analyzed across 51
360 plates spanning 2 lots of reagent kits. The intra- and inter-assay precision satisfied
361 the criteria for meeting the precision parameter with most analytes passing the
362 established criteria. Of note, COL4A1 was found to have inferior inter- and intra-
363 assay precision that ranged from 7% to 47% and 15% to 59%, respectively. Based
364 on these findings, COL4A1 was removed from consideration for inclusion in the
365 algorithm. MS serum samples ($N=1645$) were analyzed during the assay
366 development and validation process and used to establish the MS reference ranges
367 for each analyte. Sensitivity analysis demonstrated that the LLOQ and ULOQ of each
368 analyte met the sensitivity requirements established for the assay. The maximum

369 percentage of samples requiring imputation at any LOQ was 1.8% (for NfL at LLOQ)
370 **(Table 1)**.

371 **3.3 Assay interference**

372 Most biomarker interactions with interferent combinations, such as common MS
373 drugs, DMTs, and mAbs produced a median recovery that ranged from 80% to 120%
374 **(Figure 3)**. A lower percentage recovery was observed for two biomarkers, COL4A1
375 and CCL20, demonstrating a potential alteration in the presence of the sample for
376 individual drugs. COL4A1 produced a low percent recovery for several drugs that
377 ranged from 71% to 79%, which was likely an artifact of established assay
378 imprecision **(Figure 3 and Figure S2)**. For CCL20, cefoxitin spiked at 660 mg/dL
379 resulted in a median percent recovery of 77% **(Figure S2)**. Additional assay
380 interferents are shown in **Figures S2** (common drugs) and **S3** (routine endogenous
381 interferents and heterophilic antibodies).

382 **3.4 Diurnal variability**

383 Diurnal variation was evaluated in eight patients over six time points **(Figure S4)**.
384 Mean and median percent differences for each biomarker and patient were observed
385 to be within $\pm 20\%$; mean and median %CV was found to be $<30\%$ for 19 of the 21
386 biomarkers **(Table 2)**. Of note, there were some individual samples that were outside
387 of the acceptable range ($\pm 30\%$; data not shown). In addition, mean and median
388 diurnal variability $\geq 30\%$ was observed for COL4A1, which may have been due to the
389 imprecision of the assay to detect this biomarker. GH was also found to be more
390 variable compared with the other biomarkers, which is not surprising, as GH has

391 been previously reported to have a high degree of ultradian and diurnal variability.[28]

392 For this reason, GH was removed from consideration for inclusion in the algorithm.

393 **3.5 Sample stability**

394 In the initial stability study, all biomarkers were stable for up to 1 day at room

395 temperature and at 4°C, and for 28 days at -20°C. For those samples stored at room

396 temperature, CXCL13, IL-12 β , and TNFSF13B decreased beyond -20% at 3 days.

397 During a follow-up study, all biomarkers were found to meet acceptability criteria

398 when stored at 4°C, and consistent with the initial study as well as the control

399 condition (-80°C) at follow-up (**Table S4**). In a study to examine the stability of

400 samples after freeze-thaw, most biomarkers met acceptability criteria when

401 compared with fresh sample. Of note, GFAP concentrations decreased beyond -20%

402 for freeze-thaw cycles 4 and 5 (**Table S5**). Finally, score level analysis showed that

403 test conditions were within 3 SDs (± 1.5 score difference) from the control conditions

404 during the initial study (**Table S6**) and at follow-up (**Table S7**). From these findings,

405 we showed that biomarker levels were found to be most affected above certain

406 thresholds (room temperature for 24 hours, 4°C for 7 days, -20°C for 28 days, and

407 three freeze-thaws). These data can be used to establish allowable sample handling

408 and storage conditions. Beyond these empirical estimations of protein stability, it is

409 also important to note that statistically meaningful associations of biomarkers with
410 multiple MS endpoints were observed using samples that had been stored at -80°C
411 for extended periods of time. This suggests that the target epitopes for the proteins
412 that were selected for inclusion in the custom assay panel and the final algorithm
413 were sufficiently stable to derive clinically meaningful insights.

414

415 **4 CONCLUSION**

416 The accuracy, precision, and reproducibility of a biomarker assay are critical to its
417 utility as a diagnostic and prognostic tool in the management of complex
418 neurodegenerative disorders such as MS. Additionally, such an assay should be
419 insensitive to external factors such as assay interferents and sample collection,
420 processing, and storage. The Clinical and Laboratory Standards Institute and the
421 United States Food and Drug Administration issued guidance on the development
422 and validation of assays for the detection of serum-based biomarkers.[27,29,30]
423 Parameters such as accuracy, precision, recovery, sensitivity and specificity, quality
424 control, and sample stability need to be optimized for the assay to be properly
425 validated.[27,29,30] Results from our analytical validation experiments to
426 characterize the MSDA Test support that the assay is accurate, precise, sensitive,
427 specific, and robust at determining individual biomarker levels and algorithmic scores,
428 regardless of assay interferents, and validated in terms of sample stability. Our
429 findings of high accuracy and precision for the MSDA Test assay align with those of
430 other validation studies of multi-protein assays utilizing the same,[31,32] as well as
431 alternative[21,22] platforms.

432 PEA demonstrated high sensitivity, specificity, reproducibility, and repeatability
433 with low intra- and inter-assay variability, which has allowed for large-scale, high

434 throughput screening of up to 92 proteins in 96 samples simultaneously, with low
435 sample consumption and cost.[19] This platform detected novel protein biomarkers
436 and biomarker combinations for many complex disease states, such as
437 cardiovascular disease,[33-37] cancer,[32,38-40] Alzheimer's disease,[41] and
438 inflammatory diseases such as atopic dermatitis and lupus[42,43]; the platform has
439 also proven useful in aging research.[44] For the MSDA Test, we demonstrated that
440 a focused panel of MS biomarkers can be developed and optimized on the PEA
441 platform with absolute quantitation of the proteins to support a fit-for-purpose
442 analytical validation, thereby enabling clinical use of the assay.

443 Thus far, there are no validated clinical tests that leverage multiple blood
444 biomarkers to track disease activity or progression in patients with MS. This is critical
445 for a disease such as MS, which has a complicated clinical course varying from mild,
446 self-limiting to severe.[1] Although MS disease prognosis is primarily based on
447 clinical evidence, such as relapse rate and disability progression, and diagnostic tests
448 (eg, brain MRI or the presence of oligoclonal immunoglobulin G bands in the
449 CSF),[14] neither can consistently and accurately predict disease course, activity, or
450 prognosis.[13] Given the emphasis on early diagnosis and the efficacy of therapies to
451 treat early stages of the relapsing/remitting form of the disease,[4,5] validation of a
452 biomarker panel remains an unmet need in clinical practice, and use of this
453 biomarker tool should provide diagnostic and prognostic value for the treatment of
454 MS. This study demonstrated identification of biomarkers for this complex disease
455 using the PEA platform. With further clinical validation, this assay can potentially be
456 used to track disease activity and progression of MS, allowing a more personalized
457 approach to MS treatment.

458 A limitation of using a multi-protein assay is that the conditions established for
459 one biomarker are not always uniform across the full panel of biomarkers. Our

460 findings show that the MSDA Test was optimized for assessment of 18 out of the 21
461 included biomarkers and the analytical validation paradigm that we described
462 demonstrates a high level of accuracy, sensitivity, and precision with minimal cross-
463 reactivity and interference by substances commonly seen in patients with MS.

464 This study serves as a critical first step in the validation of a multi-protein,
465 serum-based assay. The next step in the validation of the MSDA Test is clinical
466 validation, which will support and confirm the association between the serum-based
467 MSDA Test and clinical and radiographic MS endpoints. Upon completion of clinical
468 validation of the assay, the final Disease Activity and Disease Pathway algorithms will
469 use the ensemble of validated proteins to expand the use of the assay by evaluating
470 biomarker correlations with endpoints associated with additional MS disease
471 assessments, selection of therapy, and differential diagnosis of patients with MS.
472 Upon successful clinical validation, this MSDA Test will be a quantitative, minimally
473 invasive, and scalable tool to improve disease management for patients with MS and
474 their physicians.

475 **ACKNOWLEDGMENTS**

476 The authors wish to thank the following team members from Olink Proteomics
477 (Uppsala, Sweden) who were involved in the development of the Multiple Sclerosis
478 Disease Activity Test assay: Erika Assarsson, Sandra Ohlsson, Martin Lundberg,
479 Jessica Bergman, and Niklas Nordberg. All authors contributed to and approved the
480 manuscript for submission. Writing and editorial assistance were provided by Jennifer
481 L. Venzie, PhD, and Bu Reinen, PhD, CMPP, of The Lockwood Group (Stamford,
482 CT, USA), and were funded by Octave Bioscience, Inc.

483

484 **CONFLICT OF INTEREST STATEMENT**

485 F. Qureshi, W. Hu, L. Loh, H. Patel and M. DeGuzman are employees of Octave
486 Bioscience, Inc. M. Becich, F. Rubio da Costa, V. Gehman, and F. Zhang were
487 employees of Octave Bioscience, Inc. at the time the study was completed. J. Foley
488 has received research support from Biogen, Novartis, Adamas, Octave Bioscience,
489 Inc., Genentech, and Mallinckrodt, received speakers' honoraria and acted as a
490 consultant for EMD Serono, Genzyme, Novartis, Biogen, and Genentech, and has
491 equity interest in Octave Bioscience Inc., and is the founder of InterPro Biosciences.
492 T. Chitnis has received compensation for consulting from Biogen, Novartis
493 Pharmaceuticals, Roche Genentech, and Sanofi Genzyme, and received research
494 support from the National Institutes of Health, National MS Society, US Department
495 of Defense, EMD Serono, I-Mab Biopharma, Mallinckrodt ARD, Novartis
496 Pharmaceuticals, Octave Bioscience, Inc., Roche Genentech, and Tiziana Life
497 Sciences.

498 **FUNDING**

499 The study was funded by Octave Bioscience, Inc. and in part by the U.S. Department
500 of Defense (W81XWH2110633 to T Chitnis).

501

502 **DATA AVAILABILITY STATEMENT**

503 Access to data can be provided after a research proposal is submitted to the
504 corresponding author and a data sharing agreement is in place.

505 **REFERENCES**

506

- 507 [1] Compston, A., Coles, A. (2008). Multiple sclerosis. *Lancet*, 372, 1502-1517.
- 508 [2] Weiner, H. L. (2004). Multiple sclerosis is an inflammatory T-cell-mediated
509 autoimmune disease. *Arch Neurol*, 61, 1613-1615.
- 510 [3] Miller, D. H., Chard, D. T., Ciccarelli, O. (2012). Clinically isolated syndromes.
511 *Lancet Neurol*, 11, 157-169.
- 512 [4] Giovannoni, G., Butzkueven, H., Dhib-jalbut, S., Hobart, J., Kobelt, G., Pepper,
513 G., . . . Vollmer, T. (2016). Brain health: time matters in multiple sclerosis. *Mult
514 Scler Relat Disord*, 9, S5-S48.
- 515 [5] Macaron, G., Ontaneda, D. (2019). Diagnosis and management of progressive
516 multiple sclerosis. *Biomedicines*, 7, 56.
- 517 [6] Miller, J. R. (2004). The importance of early diagnosis of multiple sclerosis. *J
518 Manag Care Pharm*, 10, S4-S11.
- 519 [7] Goldschmidt, T., Antel, J., König, F. B., Brück, W., Kuhlmann, T. (2009).
520 Remyelination capacity of the MS brain decreases with disease chronicity.
521 *Neurology*, 72, 1914-1921.
- 522 [8] Cunniffe, N., Coles, A. (2021). Promoting remyelination in multiple sclerosis. *J
523 Neurol*, 268, 30-44.
- 524 [9] McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H.-P., Lublin,
525 F. D., . . . Wolinsky, J. S. (2001). Recommended diagnostic criteria for multiple
526 sclerosis: guidelines from the international panel on the diagnosis of multiple
527 sclerosis. *Ann Neurol*, 50, 121-127.
- 528 [10] Thompson, A. J., Banwell, B. L., Barkhof, F., Carroll, W. M., Coetzee, T.,
529 Comi, G., . . . Cohen, J. A. (2018). Diagnosis of multiple sclerosis: 2017
530 revisions of the McDonald criteria. *Lancet Neurol*, 17, 162-173.
- 531 [11] Tintoré, M., Rovira, A., Río, J., Nos, C., Grivé, E., Téllez, N., . . . Montalban, X.
532 (2006). Baseline MRI predicts future attacks and disability in clinically isolated
533 syndromes. *Neurology*, 67, 968-972.
- 534 [12] Teixeira, M., Seabra, M., Carvalho, L., Sequeira, L., Abreu, P., Mendonça, T., .
535 . . Guimarães, J. (2020). Clinically isolated syndrome, oligoclonal bands and
536 multiple sclerosis. *Clin Exp Neuroimmunol*, 11, 33-39.
- 537 [13] Jafari, A., Babajani, A., Rezaei-Tavirani, M. (2021). Multiple sclerosis
538 biomarker discoveries by proteomics and metabolomics approaches. *Biomark
539 Insights*, 16, 11772719211013352.
- 540 [14] Ziemssen, T., Akgün, K., Brück, W. (2019). Molecular biomarkers in multiple
541 sclerosis. *J Neuroinflammation*, 16, 272.
- 542 [15] Gul, M., Jafari, A. A., Shah, M., Mirmoeeni, S., Haider, S. U., Moinuddin, S.,
543 Chaudhry, A. (2020). Molecular biomarkers in multiple sclerosis and its related
544 disorders: a critical review. *Int J Mol Sci*, 21, 6020.
- 545 [16] Hühmer, A. F., Biringer, R. G., Amato, H., Fonteh, A. N., Harrington, M. G.
546 (2006). Protein analysis in human cerebrospinal fluid: physiological aspects,
547 current progress and future challenges. *Dis Markers*, 22, 3-26.
- 548 [17] Zhang, J. (2007). Proteomics of human cerebrospinal fluid – the good, the
549 bad, and the ugly. *Proteomics Clin Appl*, 1, 805-819.
- 550 [18] Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S.,
551 Thompson, A. J., . . . Polman, C. H. (2014). Defining the clinical course of
552 multiple sclerosis: the 2013 revisions. *Neurology*, 83, 278-286.
- 553 [19] Assarsson, E., Lundberg, M., Holmquist, G., Björkstén, J., Bucht Thorsen, S.,
554 Ekman, D., . . . Fredriksson, S. (2014). Homogenous 96-plex PEA

- 555 immunoassay exhibiting high sensitivity, specificity, and excellent scalability.
556 *PLoS One*, 9, e95192.
- 557 [20] Schubert, O. T., Röst, H. L., Collins, B. C., Rosenberger, G., Aebersold, R.
558 (2017). Quantitative proteomics: challenges and opportunities in basic and
559 applied research. *Nat Protoc*, 12, 1289-1294.
- 560 [21] Dillon, R., Croner, L. J., Bucci, J., Kairs, S. N., You, J., Beasley, S., . . . Wilcox,
561 B. (2018). Analytical validation of a novel multiplex test for detection of
562 advanced adenoma and colorectal cancer in symptomatic patients. *J Pharm*
563 *Biomed Anal*, 154, 85-94.
- 564 [22] Eastman, P. S., Manning, W. C., Qureshi, F., Haney, D., Cavet, G., Alexander,
565 C., Hesterberg, L. K. (2012). Characterization of a multiplex, 12-biomarker test
566 for rheumatoid arthritis. *J Pharm Biomed Anal*, 70, 415-424.
- 567 [23] Chitnis, T., Prat, A. (2020). A roadmap to precision medicine for multiple
568 sclerosis. *Multiple Sclerosis Journal*, 26, 522-532.
- 569 [24] Bhawal, R., Oberg, A. L., Zhang, S., Kohli, M. (2020). Challenges and
570 opportunities in clinical applications of blood-based proteomics in cancer.
571 *Cancers (Basel)*, 12, 2428.
- 572 [25] Chitnis, T., Becich, M., Bove, R., Cree, B. A. C., Gehman, V., Gomez, R., . . .
573 Baranzini, S. E. Development of a custom multivariate proteomic serum based
574 assay for association with radiographic and clinical endpoints in MS.
575 Presented at: Americas Committee for Treatment and Research in Multiple
576 Sclerosis and European Committee for Treatment and Research in Multiple
577 Sclerosis; September 11-13, 2020; Virtual.
- 578 [26] Chitnis, T., Foley, J., Ionete, C., El Ayoubi, N., Saxena, S., Gaitan-Walsh, P., .
579 . . Khoury, S. J. Clinical validation study results of a multivariate proteomic
580 serum based assay for disease activity assessments in multiple sclerosis.
581 Presented at: 37th Congress of the European Committee for Treatment and
582 Research in Multiple Sclerosis (ECTRIMS); October 13-15, 2021; Virtual.
- 583 [27] Clinical and Laboratory Standards Institute. (2018). EP283CE. Defining,
584 establishing, and verifying reference intervals in the clinical laboratory. 3rd
585 edition.
- 586 [28] Hancox, T. P. M., Skene, D. J., Dallmann, R., Dunn, W. B. (2021). Tick-tock
587 consider the clock: the influence of circadian and external cycles on time of
588 day variation in the human metabolome—a review. *Metabolites*, 11, 328.
- 589 [29] United States Food and Drug Administration. Bioanalytical method validation:
590 guidance for industry. Accessed September 13, 2021.
591 <https://www.fda.gov/media/70858/download>
- 592 [30] Clinical and Laboratory Standards Institute. (2016). EP07. Interference testing
593 in clinical chemistry. 3rd edition.
- 594 [31] Xu, Y. W., Peng, Y. H., Chen, B., Wu, Z. Y., Wu, J. Y., Shen, J. H., . . . Xu, L.
595 Y. (2014). Autoantibodies as potential biomarkers for the early detection of
596 esophageal squamous cell carcinoma. *Am J Gastroenterol*, 109, 36-45.
- 597 [32] Yang, X., Suo, C., Zhang, T., Yin, X., Man, J., Yuan, Z., . . . Ye, W. (2021).
598 Targeted proteomics-derived biomarker profile develops a multi-protein
599 classifier in liquid biopsies for early detection of esophageal squamous cell
600 carcinoma from a population-based case-control study. *Biomark Res*, 9, 12.
- 601 [33] Hijazi, Z., Wallentin, L., Lindbäck, J., Alexander, J. H., Connolly, S. J.,
602 Eikelboom, J. W., . . . Siegbahn, A. (2020). Screening of multiple biomarkers
603 associated with ischemic stroke in atrial fibrillation. *J Am Heart Assoc*, 9,
604 e018984.

- 605 [34] Sanders-van Wijk, S., Tromp, J., Beussink-Nelson, L., Hage, C., Svedlund, S.,
606 Saraste, A., . . . Shah, S. J. (2020). Proteomic evaluation of the comorbidity-
607 inflammation paradigm in heart failure with preserved ejection fraction: results
608 from the PROMIS-HFpEF study. *Circulation*, *142*, 2029-2044.
- 609 [35] Pol, T., Hijazi, Z., Lindbäck, J., Oldgren, J., Alexander, J. H., Connolly, S. J., . .
610 . Wallentin, L. (2021). Using multimarker screening to identify biomarkers
611 associated with cardiovascular death in patients with atrial fibrillation.
612 *Cardiovasc Res*, cvab262.
- 613 [36] Feldreich, T., Nowak, C., Fall, T., Carlsson, A. C., Carrero, J. J., Ripsweden,
614 J., . . . Ärnlöv, J. (2019). Circulating proteins as predictors of cardiovascular
615 mortality in end-stage renal disease. *J Nephrol*, *32*, 111-119.
- 616 [37] Nowak, C., Carlsson, A. C., Östgren, C. J., Nyström, F. H., Alam, M.,
617 Feldreich, T., . . . Ärnlöv, J. (2018). Multiplex proteomics for prediction of major
618 cardiovascular events in type 2 diabetes. *Diabetologia*, *61*, 1748-1757.
- 619 [38] Leandersson, P., Åkesson, A., Hedenfalk, I., Malander, S., Borgfeldt, C.
620 (2020). A multiplex biomarker assay improves the diagnostic performance of
621 HE4 and CA125 in ovarian tumor patients. *PLoS One*, *15*, e0240418.
- 622 [39] Enroth, S., Berggrund, M., Lycke, M., Broberg, J., Lundberg, M., Assarsson,
623 E., . . . Gyllensten, U. (2019). High throughput proteomics identifies a high-
624 accuracy 11 plasma protein biomarker signature for ovarian cancer. *Commun*
625 *Biol*, *2*, 221.
- 626 [40] Berggrund, M., Enroth, S., Lundberg, M., Assarsson, E., Stålberg, K.,
627 Lindquist, D., . . . Gyllensten, U. (2019). Identification of candidate plasma
628 protein biomarkers for cervical cancer using the multiplex proximity extension
629 assay. *Mol Cell Proteomics*, *18*, 735-743.
- 630 [41] Whelan, C. D., Mattsson, N., Nagle, M. W., Vijayaraghavan, S., Hyde, C.,
631 Janelidze, S., . . . Hansson, O. (2019). Multiplex proteomics identifies novel
632 CSF and plasma biomarkers of early Alzheimer's disease. *Acta Neuropathol*
633 *Commun*, *7*, 169.
- 634 [42] Petrackova, A., Smrzova, A., Gajdos, P., Schubertova, M., Schneiderova, P.,
635 Kromer, P., . . . Kriegova, E. (2017). Serum protein pattern associated with
636 organ damage and lupus nephritis in systemic lupus erythematosus revealed
637 by PEA immunoassay. *Clin Proteomics*, *14*, 32.
- 638 [43] Brunner, P. M., He, H., Pavel, A. B., Czarnowicki, T., Lefferdink, R., Erickson,
639 T., . . . Paller, A. S. (2019). The blood proteomic signature of early-onset
640 pediatric atopic dermatitis shows systemic inflammation and is distinct from
641 adult long-standing disease. *J Am Acad Dermatol*, *81*, 510-519.
- 642 [44] Moaddel, R., Ubaida-Mohien, C., Tanaka, T., Lyashkov, A., Basisty, N.,
643 Schilling, B., . . . Ferrucci, L. (2021). Proteomics in aging research: a roadmap
644 to clinical, translational research. *Aging Cell*, *20*, e13325.
- 645

646 **FIGURE LEGENDS**

647

648 **FIGURE 1.** Incurred sample reanalysis results for (A) Individual biomarkers and (B)

649 Overall Disease Activity score, (C) Immunomodulation, (D) Neuroinflammation, (E)

650 Myelin Biology, and (F) Neuroaxonal Integrity pathway scores in the MSDA Test.

651

652 **FIGURE 2.** Accuracy of the MSDA Test to detect (A) Individual biomarkers and (B)

653 Overall Disease Activity score, (C) Immunomodulation, (D) Neuroinflammation, (E)

654 Myelin Biology, and (F) Neuroaxonal Integrity pathway scores.

655

656 **FIGURE 3.** Assay interference for common MS drugs, DMTs, and the high

657 concentration of universal mAb surrogates in the MSDA Test.

FIGURE 1




FIGURE 2





FIGURE 3



TABLES

TABLE 1 Intra- and inter-assay precision, sensitivity, and reference ranges for biomarkers in the MSDA Test

Analytes	Precision												Sensitivity and reference ranges					
	Shorter MS duration pool ^a			Longer MS duration pool ^b			RA pool			Healthy control pool			LLOQ (pg/mL)	ULOQ (pg/mL)	Low MS range (pg/mL) ^c	High MS range (pg/mL) ^d	Samples imputed at LLOQ, % (N=1645)	Samples imputed at ULOQ, % (N=1645)
	Intra %CV	Inter %CV	Conc (pg/mL)	Intra %CV	Inter %CV	Conc (pg/mL)	Intra %CV	Inter %CV	Conc (pg/mL)	Intra %CV	Inter %CV	Conc (pg/mL)						
APLP1	9	9	10,296	9	8	11,560	4	8	11,868	7	9	11,868	2323.78	142,798.49	5500	22,000	0	0
CCL20	6	9	6.9	8	7	9.2	5	9	13.7	7	9	11.8	0.92	383.49	2.1	52	0	1 (<0.1)
CD6	6	8	89	8	8	108	5	7	137	8	9	112	4.62	3318.60	46	250	0	0
CDCP1	8	9	78	8	9	125	4	9	208	7	10	72	24.22	6795.04	28	230	23 (1.4)	1 (<0.1)
CNTN2	6	7	1120	7	7	1643	4	6	1554	8	8	1256	44.46	12,373.51	650	3300	0	0
COL4A1	7	15	1104	19	20	1334	8	59	1601	47	27	1387	30.65	4573.38	520	3600	0	23 (1.4)
CXCL13	6	8	52.8	8	7	42.9	7	8	65.3	7	9	46.8	1.91	1112.70	22	190	0	0
CXCL9	6	11	31.0	8	10	62.6	5	11	112.3	7	11	27.5	1.89	1832.22	17	250	0	0
FLRT2	7	8	103	9	9	110	5	8	139	8	9	116	35.67	10,107.17	63	180	1 (<0.1)	0
GFAP	7	18	70	10	16	126	8	15	148	9	18	77	12.46	19,582.88	24	220	16 (1.0)	0
GH	7	9	823	8	7	595	5	8	1010	7	9	366	9.63	18,413.83	17	9500	7 (0.4)	9 (0.5)
IL-12β	7	9	109	9	7	122	6	8	118	8	9	71	0.56	3044.33	28	280	0	0
MOG	4	6	21.9	7	6	22.8	5	7	26.0	6	8	17.8	1.75	577.42	12	47	0	0
NFL	10	11	7.6	13	9	15.6	8	8	20.6	11	12	6.5	3.31	599.18	3.5	42	29 (1.8)	0
OPG	6	11	699	9	11	806	6	10	1022	7	12	602	14.58	62,385.21	410	1400	0	0
OPN	6	10	15,733	7	10	15,415	6	12	17,470	7	13	10,450	572.50	157,267.29	9500	39,000	0	0
PRTG	7	6	94	8	7	107	5	6	108	7	7	103	3.90	5920.73	71	180	2 (0.1)	0
SERPINA9	11	8	45.1	11	8	37.9	5	7	60.0	6	14	50.0	5.12	9286.67	12	160	1 (<0.1)	0
TNFRSF10A	9	9	5.1	9	9	5.5	5	8	7.6	9	9	4.9	0.48	1027.28	2.8	9.7	0	0
TNFSF13B	7	10	4075	11	11	4019	5	11	4204	7	13	3003	660.29	130,682.08	2300	10,000	0	0
VCAN	7	8	316	7	7	337	4	7	448	5	8	310	8.54	14,673.95	230	600	0	0

Green shading: intra- (%CV ≤ 15%) or inter-assay (%CV <20%) are within the acceptability range for the assays. Red shading: intra- (%CV >15%) or inter-assay (%CV ≥20%) precision values are outside the acceptability range for the assays.

^aAverage age of patients with shorter MS duration was 36 (range, 27–43) years.

^bAverage age of patients with longer MS duration was 52 (range, 45–62) years.

^cLow MS range was defined as the 2.5th percentile.

^dHigh MS range was defined as the 97.5th percentile.

TABLE 2 Diurnal variability of eight samples in the MSDA Test across six time points (days 1, 2, 3, 4, 5, and 12)

ANALYTE	MEAN %CV	MEDIAN %CV
<i>APLP1</i>	14	15
<i>CCL20</i>	25	21
<i>CD6</i>	10	7
<i>CDCP1</i>	12	12
<i>CNTN2</i>	11	10
<i>COL4A1</i>	44	39
<i>CXCL13</i>	18	11
<i>CXCL9</i>	13	11
<i>FLRT2</i>	10	8
<i>GFAP</i>	13	12
<i>GH</i>	78	79
<i>IL-12B</i>	10	9
<i>MOG</i>	12	11
<i>NFL</i>	17	17
<i>OPG</i>	11	10
<i>OPN</i>	10	8
<i>PRTG</i>	8	6
<i>SERPINA9</i>	12	12
<i>TNFRSF10A</i>	10	12
<i>TNFSF13B</i>	11	8
<i>VCAN</i>	10	7

Green shading: %CV ≤30%. Red shading: %CV >30%.

**Analytical Validation of a multi-protein, proteomic serum-based assay for
disease activity assessments in multiple sclerosis**

Ferhan Qureshi,* Wayne Hu,* Louisa Loh, Hemali Patel, Maria DeGuzman,
Michael Becich, Fatima Rubio da Costa, Victor Gehman, Fujun Zhang, John Foley,
Tanuja Chitnis

*These authors contributed equally to this work


Supporting Information

FILE S1. MSDA Test algorithm formula

Key to the MSDA Test was the architecture of a stacked classifier (in the mlxtend [1] framework) where each node (blue boxes in the **Figure**) in both layers are L2-regularized logistic regression models from Scikit Learn.[2] The input layer read in demographically corrected for age and sex, \log_{10} , LOQ-imputed concentrations of proteins associated with four physiological pathways from each sample and generated probabilities that the sample in question was positive for the presence of Gd+lesions. The meta-classifier (output) layer of the model ingested the probabilities from each pathway model along with all of the protein concentrations that fed the first layer and generated an overall probability that the sample in question was Gd+lesion-positive. This probability was then mapped into a Disease Activity score by being shifted, scaled, rounded, and clipped to the nearest half point over a range from 1 to 10 (Eq. 1). A similar process converted the pathway probabilities into pathway scores after the pathway probabilities were adjusted so that for each sample, the mean over the adjusted pathway probabilities was equal to the Disease Activity probability for each sample (Eq. 2). The datasets used to develop and evaluate the demographic correction, four Disease Pathway models, and Disease Activity model, as well as the performance of these models, have been described previously.[2]

The process for calculating the Disease Activity score is shown in the **Figure**.

FIGURE. Schematic representation of the Disease Activity score calculation from protein concentrations (green) to both layers of the stacked classifier (blue), the output Disease Activity probability (red), and the final Disease Activity and Disease Pathway score (black).



The overall Disease Activity score had the mathematical form:

$$S_{DA} = \text{Clip}_0^9 \left(\frac{1}{2} \text{Round} \left(18 \times \frac{P_{DA} - P_{DA}^{Low}}{P_{DA}^{High} - P_{DA}^{Low}} \right) \right) + 1 \quad (1)$$

The “Clip” function limited the output of its argument to between 0 and 9. The “Round” function rounded to the nearest whole number. P_{DA} was the Disease Activity probability output from the final stage of the stacked classifier model. P_{DA}^{High} and

P_{DA}^{Low} were probability clip values chosen for the overall Disease Activity (and each pathway) to maximize the range of the score over the entire training data set. Their values are tabulated below.

Similar to the Disease Activity score, each pathway score was computed from the pathway probabilities with the additional step of recentering the ensemble of pathway probabilities around the Disease Activity probability for each sample:

$$S_{pth} = \text{Clip}_0^9 \left(\frac{1}{2} \text{Round} \left(18 \times \left(\frac{P_{pth} - P_{pth}^{Low}}{P_{pth}^{High} - P_{pth}^{Low}} + \frac{P_{DA} - P_{DA}^{Low}}{P_{DA}^{High} - P_{DA}^{Low}} - \frac{1}{N_{pth}} \sum_{pth'} \frac{P_{pth'} - P_{pth'}^{Low}}{P_{pth'}^{High} - P_{pth'}^{Low}} \right) \right) \right) + 1 \quad (2)$$

“Clip” and “Round” served the same purpose in Eq. 2 as in Eq.1. P_{pth} was the probability for pathway model pth . P_{DA} was again the probability output by the final stage of the stacked classifier. The “High” and “Low” P s for each pth served a similar purpose to those for the Disease Activity: rescaling the model probabilities so that they had a larger dynamic range. Lastly, N_{pth} was the number of pathway models that fed into the final layer of the stacked classifier model. In this case, $N_{pth}=4$.

The probabilities associated with each layer of the stacked classifier had a closed analytic form as well. Working backward from the final Disease Activity score, the Disease Activity probability had the form:

$$P_{DA} = \frac{1}{1 + e^{-(C_{DA}^0 + \sum_{feat} C_{feat} V_{feat})}} \quad (3)$$

C_{DA}^0 was the intercept (or bias) value for the Disease Activity meta-classifier. C_{feat} was the coefficient associated with V_{feat} . V_{feat} was the value of the feature being summed, either the probability for one of the pathways from the first layer of the model (written out explicitly in Eq. 4) or the age- and sex- corrected, \log_{10} , LOQ-imputed concentrations that fed into the first-layer pathway models. These meta-

classifier coefficients were fit using L2-penalized logistic regression with Gd+ lesion presence as the dependent variable, an intercept, and the stacked classifier features as the independent variables, with inverse regularization strength $C=1.0$, balanced class weight, and tolerance $=0.0001$, with the ‘lbfgs’ solver.

The individual pathway probabilities had the form:

$$P_{pth} = \frac{1}{1 + e^{-(C_{pth}^0 + \sum_{prot} C_{prot} V_{prot})}} \quad (4)$$

C_{pth}^0 was the intercept value for the pathway model in question. C_{prot} was the coefficient for a protein in pathway pth . V_{prot} was the demographically corrected, \log_{10} , LOQ-imputed concentration of protein $prot$. These coefficients were fit using L2-penalized logistic regression with Gd+ lesion presence as the dependent variable, an intercept, and the pathway’s demographically corrected (for age, sex), \log_{10} , LOQ-imputed protein concentrations as the independent variables. The final pathway coefficients were the result of a stratified, 10-fold cross-validation with 3 repeats, grid-searched over inverse regularization strength $C=[100, 10, 1.0, 0.1, 0.01]$, class weights=[None, balanced], solvers=["saga," "lbfgs," "liblinear"], and tolerances=[0.01, 0.001, 0.0001]. The demographic correction for the \log_{10} of the LOQ-imputed protein concentration had the form:

$$V_{prot} = \log_{10} \left(A_{prot} \left[\frac{pg}{mL} \right] \right) - [D_{prot,0} + (D_{prot,Sex} \times Sex) + (D_{prot,Age} \times Age[years])] \quad (5)$$

A_{prot} was the LOQ-imputed absolute concentration of protein $prot$ in pg/mL (the units of these direct measurements have been written explicitly for added clarity).

$D_{prot,0}$, $D_{prot,Sex}$, and $D_{prot,Age}$ were the intercept, sex, and age coefficients for demographic correction, respectively. These coefficients were fit using the following procedure on three datasets not reported here. The dataset used to train the stacked classifier and pathway models provided the final non-zero coefficients for the

demographic correction. The demographic correction coefficients were fit independently on each dataset using linear regression using StatsModels OLS[4] with \log_{10} , LOQ-imputed protein concentration as the dependent variable, an intercept, and age and sex as the independent variables, after outliers were removed. Outliers were defined for each dataset as ≥ 96 th percentile or ≤ 4 th percentile for \log_{10} , LOQ-imputed protein concentration. After fitting the linear regression, the age and sex coefficients were set to zero if the 95% confidence interval contained zero in any of the three datasets or if the sign of the coefficient was not consistent across three datasets. Sex was 0 for women and 1 for men, and age was the patient's age in years at time of blood draw.

Finally, see below for tables of the coefficients used in each step of the scoring process. First, we tabulated the demographic correction coefficients. These were the D_s in Eq. 5.

Protein	Sex	Age	Intercept
APLP1	-0.052	0	4.065
CCL20	0	0	1.088
CD6	0	0	1.959
CDCP1	0	0.006	1.64
CNTN2	0	0.002	3.128
CXCL13	0	0	1.819
CXCL9	0	0.005	1.419
FLRT2	0	0	1.968
GFAP	-0.05	0.005	1.692
IL-12B	0	0	2.062
MOG	-0.04	0.003	1.267
NfL	0	0.008	0.5
OPG	-0.014	0.002	2.743

OPN	0.045	0	4.172
PRTG	0	0	2.052
SERPINA9	0	0	1.56
TNFRSF10A	0	0.003	0.565
TNFSF13B	0	0	3.75

Next, we tabulated the protein coefficients for each pathway. These were the C_s in Eq. 4.

- Neuroinflammation:

Feature	Coefficient
CCL20	0.397
CD6	0.243
CXCL13	0.668
CXCL9	0.778
IL-12B	-1.515
TNFRSF10A	0.089
TNFSF13B	-2.705
Intercept	-0.283

- Immunomodulation:

Feature	Coefficient
CD6	0.825
CDCP1	-0.633
CXCL13	1.075
CXCL9	1.178
IL-12B	-1.657
TNFSF13B	-4.232
Intercept	-0.483

- Neuroaxonal Integrity:

Feature	Coefficient
APLP1	-0.149
CNTN2	-0.434
FLRT2	-0.321
GFAP	0.024
NfL	2.998
OPG	0.384

OPN	0.026
PRTG	-0.621
SERPINA9	-0.779
TNFRSF10A	-0.284
Intercept	-0.744

- Myelin Biology:

Feature	Coefficient
APLP1	-1.206
MOG	2.653
OPN	-0.037
Intercept	-0.552

Then we tabulated the meta-classifier coefficients for the second stage of the stacked classifier. These were the Cs in Eq. 3.

Feature	Coefficient
APLP1	-0.363
CCL20	0.222
CD6	0.119
CDCP1	-0.524
CNTN2	-0.21
CXCL13	0.1
CXCL9	0.252
FLRT2	-0.111
GFAP	0.042
IL-12B	-0.432
MOG	0.485
NfL	2.038
OPG	0.056
OPN	-0.072
PRTG	0.768
SERPINA9	0.142
TNFRSF10A	-0.178
TNFSF13B	-1.3
Neuroinflammation pathway	1.14

classifier	
Immunomodulation pathway classifier	1.737
Neuroaxonal integrity pathway classifier	1.525
Myelin biology pathway classifier	0.435
Intercept	-2.51

Finally, we tabulated the low and high values for scaling the probabilities in Eq.1 and Eq.2.

Disease Pathway/Disease Activity score	$P_{Low\ pth}$	$P_{High\ pth}$
Disease Pathway		
Immunomodulation	0.05	1.0
Myelin Biology	0.2	0.6
Neuroaxonal Integrity	0.1	1.0
Neuroinflammation	0.15	0.95
Disease Activity	0.05	1.00

Abbreviations: $P_{High\ pth}$, high values for scaling probabilities; $P_{Low\ pth}$, low values for scaling probabilities.

FILE S2. Assay interferences

Samples were analyzed for potential interference with endogenous substances found naturally in patients' samples (eg, lipemia, hemolysis, high protein count, and high bilirubin levels) and heterophilic antibodies such as HAMA and RF. Serum pools ($n=4$) were spiked with bilirubin, hemolysate, and lipids at typical concentrations using the ASSURANCE™ Interference Test Kit (Sun Diagnostics).

Heterophilic antibodies, including RF and HAMA, are established sources of potential interference in immunoassays. RF concentrate (Lee BioSolutions, Maryland Heights, MO, USA) was used to spike six serum samples at low (150 IU/mL) and high (2000 IU/mL) concentrations to determine the effect of RF interference on the analysis. For HAMA interference, five HAMA-positive serum samples with known established HAMA levels (ASSURANCE™ Interference Test Kit) were mixed at different ratios (10:90; 50:50; 90:10) with four MS samples from an internal cohort. Two HAMA-positive samples had a titer level >240 and three samples had a titer level >480 , indicating that the positive samples had either >240 or >480 times more activity than a known negative. The mixed samples were compared with expected ratios of the individually measured samples to calculate the percent recovery.

Except for heterophilic antibody interference, the mean percentage recovery was calculated relative to the corresponding spike control (representing the same alteration of the serum sample without the addition of the interferent). For heterophilic antibody interference, the mean percentage recovery was calculated by comparing the RF spiked (low and high concentrations) samples with a corresponding spike control.

TABLE S1 Protein biomarkers included in assay panel to perform the MSDA Test

Biomarker	Full name	UniProt identifier
<i>APLP1</i>	Amyloid beta precursor-like protein 1	P51693
<i>CCL20</i>	C-C motif chemokine ligand 20 (MIP 3-alpha)	P78556
<i>CD6</i>	Cluster of differentiation 6	P30203
<i>CDCP1</i>	CUB domain-containing protein 1	Q9H5V8
<i>CNTN2</i>	Contactin 2	Q02246
<i>CXCL13</i>	Chemokine (C-X-C motif) ligand 13	P02462
<i>CXCL9</i>	Chemokine (C-X-C motif) ligand 9 (MIG)	O43927
<i>COL4A1</i> ^a	Collagen type IV alpha 1	Q07325
<i>FLRT2</i>	Fibronectin leucine-rich repeat transmembrane protein	O43155
<i>GFAP</i>	Glial fibrillary acidic protein	P14136
<i>GH</i> ^a	Growth hormone (somatotropin)	P01241
<i>IL-12β</i>	Interleukin-12 subunit beta	P29460
<i>MOG</i>	Myelin oligodendrocyte glycoprotein	Q16653
<i>NfL</i>	Neurofilament light polypeptide chain	P07196
<i>OPG</i>	Osteoprotegerin	O00300
<i>OPN</i>	Osteopontin	P10451
<i>PRTG</i>	Protogenin	Q2VWP7
<i>SERPINA9</i>	Serpin family A member 9	Q86WD7
<i>TNFRSF10A</i>	Tumor necrosis factor receptor superfamily member 10A (TRAIL-R1)	O00220
<i>TNFSF13B</i>	Tumor necrosis factor superfamily member 13B (BAFF)	Q9Y275
<i>VCAN</i> ^a	Versican core protein	P13611

^aThese biomarkers were not used in the algorithm to determine Disease Pathway and Disease Activity scores.

TABLE S2 Common over-the-counter and prescription drugs, reference materials and standards, and mAbs evaluated for interference in the MSDA Test

Assay interferents	Concentration
Common drugs	
Acetaminophen	15.6 mg/dL
Ampicillin Na	7.5 mg/dL
Acetylsalicylic acid	3 mg/dL
Doxycycline HCl	1.8 mg/dL
Cefoxitin Na	660 mg/dL
Heparin	3300 U/L
Cyclosporine	0.18 mg/dL
Levodopa	0.75 mg/dL
Ibuprofen	21.9 mg/dL
Methyldopa	2.25 mg/dL
Phenylbutazone	32.1 mg/dL
Metronidazole	12.3 mg/dL
Rifampicin	4.8 mg/dL
Theophylline	6 mg/dL
Acetylcysteine	15 mg/dL
Reference materials and standards to evaluate DMTs	
Interferon β -1A (Avonex, Rebif)	0.56 ng/mL
Dimethyl fumarate (Tecfidera)	3.74 μ g/mL
Fingolimod (Gilenya)	8.8 ng/mL
Teriflunomide (Aubagio)	90.6 μ g/mL
Mitoxantrone (Novantrone)	0.674 μ g/mL
Rituximab (Rituxan)	370 μ g/mL
Methylprednisolone	0.141 μ g/mL
Cladribine (Mavenclad)	0.058 μ g/mL
Glatiramer acetate (Copaxone, Glatopa)	1.0 μ g/mL
Vitamin D2 (Ergocalciferol)	0.2 μ g/mL

Universal mAb surrogates^a

High concentration

424 µg/mL

Low concentration

7.93 µg/mL

^aSurrogates for natalizumab, ocrelizumab, alemtuzumab, and ofatumumab.

TABLE S3 Lot to lot (batch 1 vs. batch 2) and laboratory to laboratory (development vs. clinical laboratory) consistency of the MSDA Test

	Mean % difference		R ² correlation of samples	
	Batch 1 vs. batch 2	Development vs. clinical laboratory	Batch 1 vs. batch 2	Development vs. clinical laboratory
<i>APLP1</i>	0	-1	0.93	0.95
<i>CCL20</i>	-14	-12	0.99	1.00
<i>CD6</i>	-9	-9	0.97	0.97
<i>CDCP1</i>	-9	-10	0.99	1.00
<i>CNTN2</i>	8	4	0.96	0.97
<i>COL4A1</i>	-27	-17	0.97	0.98
<i>CXCL13</i>	-7	-5	0.99	1.00
<i>CXCL9</i>	-16	-11	1.00	1.00
<i>FLRT2</i>	-3	-6	0.95	0.98
<i>GFAP</i>	-13	-9	0.96	0.97
<i>GH</i>	-3	-6	0.98	0.99
<i>IL-12β</i>	-5	-5	0.97	0.98
<i>MOG</i>	2	0	0.98	0.98
<i>NfL</i>	-13	-10	0.98	0.99
<i>OPG</i>	-17	-9	0.97	0.98
<i>OPN</i>	-14	-7	0.97	0.99
<i>PRTG</i>	0	-5	0.97	0.98
<i>SERPINA9</i>	-4	-5	0.99	0.99
<i>TNFRSF10A</i>	-7	-11	0.98	0.99
<i>TNFSF13B</i>	-6	-5	0.96	0.98

VCAN	-8	-9	0.91	0.95
------	----	----	------	------

TABLE S4 Storage, processing, and stability of the individual biomarkers at various temperatures (room temperature, 4°C, and -20°C) over time during the initial and follow-up studies

Analyte	Mean % difference vs. experimental control conditions																					
	Initial study												Follow-up study									
	Room temperature						4°C						-20°C						4°C			
	4 h	Day 1	Day 3	Day 7	Day 14	Day 28	4 h	Day 1	Day 3	Day 7	Day 14	Day 28	Day 1	Day 3	Day 7	Day 14	Day 28	Day 1	Day 2	Day 3	Day 7	
<i>APLP1</i>	4	17	7	19	48	134	-6	-8	12	31	12	25	5	9	0	5	10	10	5	7	11	
<i>CCL20</i>	4	2	-6	-7	8	47	1	-3	11	24	15	23	12	13	6	5	7	-1	-2	4	12	
<i>CD6</i>	-2	-4	-14	-5	19	93	-10	1	-7	7	-2	10	1	5	-1	1	1	2	-1	2	5	
<i>CDCP1</i>	-5	-1	-13	-2	26	114	-10	0	-2	6	1	10	0	7	-3	1	1	4	1	3	4	
<i>CNTN2</i>	0	-3	-13	-3	24	71	-8	0	-9	2	-3	7	2	6	1	2	3	3	0	1	1	
<i>COL4A1</i>	-5	-3	-14	-1	22	91	-10	1	-12	2	-2	10	0	4	9	3	2	9	-3	11	14	
<i>CXCL13</i>	-1	-7	-25	-27	-2	4	7	-5	-6	-8	-6	-4	-3	6	12	4	7	5	2	0	0	1

CXCL9	-2	-4	-14	-7	16	65	-6	-1	0	-11	-4	-6	-2	2	6	1	3	4	4	0	1	0
FLRT2	-4	-1	-11	0	26	97	-10	-1	0	-2	11	2	13	-1	8	-1	1	2	3	0	2	3
GFAP	0	2	-5	9	39	142	-7	-9	-5	20	1	18	3	11	-1	3	9	1	3	4	8	
GH	1	0	-10	-6	9	52	-6	-9	2	10	7	12	4	9	1	5	7	2	3	2	10	
IL-12β	-2	-13	-34	-40	2	-24	-7	-1	1	-14	-18	-9	-15	3	8	0	3	4	3	0	1	-4
MOG	-2	0	-10	1	23	83	-7	-9	-1	13	2	12	1	6	1	3	3	1	2	1	3	
NfL	-3	-6	-11	2	29	110	-11	-9	1	4	3	12	-4	4	0	2	2	-3	6	1	6	
OPG	-2	-4	-13	-5	18	94	-6	-9	-8	1	-1	5	1	6	-1	2	2	2	0	1	1	
OPN	-4	-5	-18	-13	1	47	-6	-1	6	-27	-24	-26	-26	0	5	-1	3	-1	2	-2	-2	-8
PRTG	-1	-6	-19	-20	3	-1	-6	-8	-7	-3	-4	-1	3	6	0	2	2	2	0	1	0	0
SERPINA9	-1	-3	-15	-8	10	43	-7	-1	1	-4	2	0	3	1	5	-1	1	2	9	10	7	9
TNFRSF10A	0	-2	-11	0	31	108	-7	-1	1	1	11	3	10	0	9	-2	0	2	5	0	2	5
TNFSF13B	-4	-7	-20	-10	19	108	-10	-1	4	-12	0	-6	1	1	7	1	3	2	3	-1	3	-1

medRxiv preprint doi: <https://doi.org/10.1101/2022.05.23.22275201>; this version posted January 25, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

VCAN	-3	-3	-10	-1	23	72	-6	-1	-1	9	0	7	0	4	-2	2	1	5	2	4	7
------	----	----	-----	----	----	----	----	----	----	---	---	---	---	---	----	---	---	---	---	---	---

Green shading: %CV within ±20%. Red shading: %CV < -20% or >20%.

TABLE S5 Storage, processing, and stability of the MSDA Test during various freeze-thaw cycles for individual biomarkers

Analyte	Freeze-thaw cycle				
	Cycle 1	Cycle 2	Cycle 3	Cycle 4	Cycle 5
<i>APLP1</i>	-6	6	-13	-5	-7
<i>CCL20</i>	-7	-2	-13	-10	-11
<i>CD6</i>	-1	0	-9	-8	-7
<i>CDCP1</i>	-1	-1	-11	-8	-7
<i>CNTN2</i>	1	3	-6	-1	-3
<i>COL4A1</i>	2	3	-11	-5	-7
<i>CXCL13</i>	-1	-5	-11	-10	-9
<i>CXCL9</i>	-1	1	-11	-5	-7
<i>FLRT2</i>	-2	-3	-10	-10	-8
<i>GFAP</i>	-9	-4	-20	-23	-28
<i>GH</i>	-7	1	-12	-15	-13
<i>IL-12β</i>	-4	0	-13	-7	-9
<i>MOG</i>	-3	1	-11	-7	-9
<i>NfL</i>	1	-2	-12	-12	-1
<i>OPG</i>	-1	-3	-11	-6	-8
<i>OPN</i>	-3	-2	-11	-7	-9
<i>PRTG</i>	-3	-1	-10	-9	-8
<i>SERPINA9</i>	13	-2	-13	-11	-12
<i>TNFRSF10A</i>	-8	2	-12	-8	-9
<i>TNFSF13B</i>	-1	0	-9	-4	-7
<i>VCAN</i>	-1	1	-8	-4	-6

Green shading: average % difference within $\pm 20\%$. Red shading: average % difference $< -20\%$.

TABLE S6 Initial study of the storage, processing, and stability of the MSDA Test at various temperatures (room temperature, 4°C, and -20°C) over time and during freeze-thaw at the Disease Activity score level

Sample ID	-80° C	Room temperature						-80° C	4°C						-80°C	-20 C					Sample ID	Freeze-thaw					
		4 h	Day 1	Day 3	Day 7	Day 14	Day 28		4 h	Day 1	Day 3	Day 7	Day 14	Day 28		Day 1	Day 3	Day 7	Day 14	Day 28		Fresh	1	2	3	4	5
A	3	3	3	3	3	3	2.5	3	3.5	2.5	3	3.5	3.5	3	3	2.5	3	3.5	2.5	2.5	E	5	5.5	5	5	4	5.5
B	4	4.5	4.5	4.5	4.5	4.5	3.5	4	4	5	4.5	4.5	5	5	4	4.5	4.5	4.5	5	5	F	6.5	7	6.5	7	6.5	7
C	7	6.5	6	7	7	6.5	6.5	7	7	7.5	7	7	7.5	7	7	6	6.5	7	6.5	7	G	3	3.5	3	3.5	3.5	3.5
D	9	8.5	8.5	9	9	9	8.5	9	9	8.5	9	9	9	9	9	8.5	9	9	8.5	8.5	H	2.5	3	2.5	2.5	2.5	3

Low (1.0-4.0) Disease Activity scores are noted in green, moderate (4.5-7.0) Disease Activity scores are noted in blue, and high (7.5-10.0) Disease Activity scores are noted in orange.

TABLE S7 Follow-up study of the storage, processing, and stability of the MSDA

Test at 4°C over time at the Disease Activity score level

Sample ID	-80°C	4°C			
		Day 1	Day 2	Day 3	Day 7
A	8.5	8.5	8.5	8.5	8.5
B	5	4.5	4.5	4.5	4.5
C	7.5	6	7.5	7.5	7
D	6.5	6.5	6.5	5.5	7
E	5	5	5	5	5.5
F	7	7	7	6.5	7.5
G	5.5	5	5	5	5.5
H	6.5	6.5	7.5	7.5	7.5
I	6	6	6.5	6	7
J	3.5	3.5	3	3.5	3
K	1.5	1	1.5	1.5	1.5
L	2.5	2.5	2.5	2.5	2
M	2.5	2.5	3	2	3
N	7.5	7.5	8.5	8	8

Low (1.0□4.0) Disease Activity scores are noted in green, moderate (4.5□7.0) Disease Activity scores are noted in blue, and

high (7.5□10.0) Disease Activity scores are noted in orange.

FIGURE S1. Overview of PEA technology and MSDA Test format. Eighteen antibody pairs, labeled with DNA oligonucleotides, bind to target antigen in solution.

Oligonucleotides that are brought into proximity will hybridize and are extended by a DNA polymerase. This newly created piece of DNA barcode is amplified by PCR. The amount of each DNA barcode is quantified by microfluidic qPCR (Biomark™ HD, Fluidigm, Maryland Heights, MO, USA), with results reported in cycle threshold values. Data processing is then performed in the Olink® NPX Manager (Olink Proteomics, Uppsala, Sweden) software to convert the Ct values to a Normalized Protein eXpression value. The signal obtained from the assay (Normalized Protein eXpression) is converted to absolute concentration (pg/mL) using three calibrators that cover the range of sample response in the MS population (calibrators: high, middle, low) and then referenced back to the standard curve. These concentrations are then used as inputs into algorithms corresponding to disease activity and biological pathway scores.




FIGURE S2. Assay interference using common drugs.




FIGURE S3. Assay interference using routine endogenous interferents and heterophilic antibodies.





FIGURE S4. Percent difference of the observed protein concentration relative to the average concentration as determined from six time points (days 1, 2, 3, 4, 5, and 12) in eight samples assayed in the MSDA Test.



REFERENCES

- [1] Raschka, S. (2018). MLxtend: providing machine learning and data science utilities and extensions to Python's scientific computing stack. *J Open Source Softw*, 3, 638.
- [2] Pedregosa, F., Varoquaux, G., Gramfort, A., Michel, V., Thirion, B., Grisel, O., ... Duchesnay, E. (2011). Scikit-learn: Machine learning in Python. *Journal of Machine Learning Research*, 12, 2825–2830.
- [3] Chitnis, T., Foley, J., Ionete, C., El Ayoubi, N., Saxena, S., Gaitan-Walsh, P., ... Khoury, S. J. Clinical validation study results of a multivariate proteomic serum based assay for disease activity assessments in multiple sclerosis. Presented at: 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); October 13-15, 2021; Virtual.
- [4] Seabold, S., Perktold, J. (2010). Statsmodels: Econometric and statistical modeling with Python. *Proceedings of the 9th Python in Science Conference*, 92–96.